FDA.reportPublic FDA data

SEMAGLUTIDE - Food and Drug Administration

Set ID
21318a8d-e167-4f44-9627-3daede9532ff
Type
Indexing - product concept
Effective date
2020-02-27
Version
1
Source
DailyMed source

Mapped DailyMed Labels#

Label, Relation, Manufacturer table
LabelRelationManufacturerEffective
These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use WEGOVY (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk Pharmaceutical Industries, LP | Novo Nordisk A/S - 25a-B2026-06-18
These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameNovo Nordisk Pharmaceutical Industries, LP2026-06-01
These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameNovo Nordisk Pharmaceutical Industries, LP2026-05-19
These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use WEGOVY (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk Pharmaceutical Industries, LP2026-05-05
These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use WEGOVY (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk2026-03-19
These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use WEGOVY (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk2026-02-25
These highlights do not include all the information needed to use RYBELSUS ® and OZEMPIC ® tablets safely and effectively. See full prescribing information for RYBELSUS and OZEMPIC tablets. RYBELSUS (semaglutide) tablets, for oral use OZEMPIC (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk Pharmaceutical Industries, LP2026-01-30
These highlights do not include all the information needed to use RYBELSUS ® and OZEMPIC ® tablets safely and effectively. See full prescribing information for RYBELSUS and OZEMPIC tablets. RYBELSUS (semaglutide) tablets, for oral use OZEMPIC (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk Pharmaceutical Industries, LP2026-01-30
These highlights do not include all the information needed to use RYBELSUS ® and OZEMPIC ® tablets safely and effectively. See full prescribing information for RYBELSUS and OZEMPIC tablets. RYBELSUS (semaglutide) tablets, for oral use OZEMPIC (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk2026-01-30
These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use WEGOVY (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk2026-01-30
These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use WEGOVY (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk2025-12-22
These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameNovo Nordisk2025-11-21
These highlights do not include all the information needed to use RYBELSUS ® safely and effectively. See full prescribing information for RYBELSUS . RYBELSUS (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk2025-10-17
These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameNovo Nordisk | Novo Nordisk A/S | Novo Nordisk Pharmaceutical Industries, LP2025-10-14
These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameNovo Nordisk | Novo Nordisk A/S | Novo Nordisk Pharmaceutical Industries, LP2025-10-14
These highlights do not include all the information needed to use WEGOVY safely and effectively. See full prescribing information for WEGOVY. WEGOVY ® (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameNovo Nordisk2025-10-14
These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameNovo Nordisk2025-08-01
These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameNovo Nordisk | Novo Nordisk A/S | Novo Nordisk Pharmaceutical Industries, LP2025-01-02
These highlights do not include all the information needed to use RYBELSUS ® safely and effectively. See full prescribing information for RYBELSUS . RYBELSUS (semaglutide) tablets, for oral use Initial U.S. Approval: 2017Product nameNovo Nordisk2024-12-09
These highlights do not include all the information needed to use WEGOVY safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameA-S Medication Solutions2024-04-23
These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameA-S Medication Solutions2023-11-22
These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameA-S Medication Solutions2023-11-17
These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameA-S Medication Solutions2021-01-14
These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017Product nameA-S Medication Solutions2020-09-17